Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics

Travere Therapeutics, Inc. (TVTX): $7.71

0.04 (+0.52%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add TVTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#249 of 363

in industry

TVTX Price/Volume Stats

Current price $7.71 52-week high $23.17
Prev. close $7.67 52-week low $5.25
Day low $7.41 Volume 776,017
Day high $7.98 Avg. volume 1,235,802
50-day MA $8.25 Dividend yield N/A
200-day MA $10.38 Market Cap 586.72M

TVTX Stock Price Chart Interactive Chart >

TVTX POWR Grades

  • Value is the dimension where TVTX ranks best; there it ranks ahead of 74.29% of US stocks.
  • TVTX's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • TVTX ranks lowest in Stability; there it ranks in the 10th percentile.

TVTX Stock Summary

  • Over the past twelve months, TVTX has reported earnings growth of -69.96%, putting it ahead of merely 18.99% of US stocks in our set.
  • In terms of volatility of its share price, TVTX is more volatile than 89.37% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TVTX comes in at -32.61% -- higher than that of just 10.75% of stocks in our set.
  • Stocks that are quantitatively similar to TVTX, based on their financial statements, market capitalization, and price volatility, are LGVN, FCEL, WATT, LCTX, and ONVO.
  • TVTX's SEC filings can be seen here. And to visit TRAVERE THERAPEUTICS INC's official web site, go to www.retrophin.com.

TVTX Valuation Summary

  • TVTX's price/sales ratio is 3.2; this is 23.81% lower than that of the median Healthcare stock.
  • TVTX's price/sales ratio has moved NA NA over the prior 134 months.

Below are key valuation metrics over time for TVTX.

Stock Date P/S P/B P/E EV/EBIT
TVTX 2023-12-29 3.2 2.4 -7.8 -12.4
TVTX 2023-12-28 3.4 2.5 -8.1 -12.9
TVTX 2023-12-27 3.4 2.6 -8.2 -13.0
TVTX 2023-12-26 3.4 2.5 -8.1 -12.9
TVTX 2023-12-22 3.2 2.4 -7.8 -12.5
TVTX 2023-12-21 3.1 2.3 -7.4 -12.1

TVTX Growth Metrics

    The 5 year revenue growth rate now stands at 32.8%.
  • Its 3 year net income to common stockholders growth rate is now at -61.4%.
  • The year over year net income to common stockholders growth rate now stands at 9.78%.
Over the past 37 months, TVTX's revenue has gone up $36,680,000.

The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 212.018 -186.291 -278.482
2022-09-30 213.399 -158.528 -264.232
2022-06-30 228.12 -86.94 -230.215
2022-03-31 228.57 -43.638 -202.195
2021-12-31 227.49 -14.792 -180.091
2021-09-30 221.224 -1.785 -250.14

TVTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TVTX has a Quality Grade of C, ranking ahead of 60.91% of graded US stocks.
  • TVTX's asset turnover comes in at 0.306 -- ranking 150th of 681 Pharmaceutical Products stocks.
  • VTVT, FBRX, and NATR are the stocks whose asset turnover ratios are most correlated with TVTX.

The table below shows TVTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.306 0.969 -0.399
2021-06-30 0.291 0.968 -0.396
2021-03-31 0.289 0.968 -0.412
2020-12-31 0.311 0.969 -0.361
2020-09-30 0.304 0.970 -0.166
2020-06-30 0.303 0.967 -0.194

TVTX Price Target

For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.25 (Strong Buy)

Travere Therapeutics, Inc. (TVTX) Company Bio


Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.


TVTX Latest News Stream


Event/Time News Detail
Loading, please wait...

TVTX Latest Social Stream


Loading social stream, please wait...

View Full TVTX Social Stream

Latest TVTX News From Around the Web

Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU). Classical HCU is a rare genetic

Yahoo | December 14, 2023

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgAN to full approval Following engagement with the FDA on the two-year results from the Phase 3 DUPLEX Study in FSGS, Company conducting additional analyses of FSGS data and plans to re-engage FDA in 2024 Company is implementing a strategic reorganization to further focus near-term resources on ongoing FI

Yahoo | December 4, 2023

Travere Therapeutics (NASDAQ:TVTX) shareholders have endured a 74% loss from investing in the stock three years ago

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...

Yahoo | December 3, 2023

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET. A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for li

Yahoo | November 21, 2023

Travere Therapeutics Reports Third Quarter 2023 Financial Results

Received 430 new patient start forms for FILSPARI® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI totaled $8 million for the third quarter of 2023 Phase 3 PROTECT and DUPLEX Studies of sparsentan presented as ASN Kidney Week Late Breakers and simultaneously published in The Lancet and NEJM, respectively Completed sale of bile acid product portfolio for up to $445 million including potential future milestone-based payments, adv

Yahoo | November 7, 2023

Read More 'TVTX' Stories Here

TVTX Price Returns

1-mo -7.22%
3-mo -14.24%
6-mo -13.76%
1-year -66.32%
3-year -67.01%
5-year N/A
YTD -14.24%
2023 -57.25%
2022 -32.25%
2021 13.89%
2020 91.94%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!